Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer

Clinical Breast Cancer

Volumn 14, Issue 2, 2014, Pages 94-100

  Luu, Thehang ^a   Frankel, Paul ^a   Chung, Cathie ^a   Chow, Warren ^a   Mortimer, Joanne ^a   Hurria, Arti ^a   Somlo, George ^a  

^a Department of Medical Oncology and Therapeutics Research City of Hope ^*  (United States)

Author keywords

Bevacizumab; Kinase inhibitor; Metastatic breast cancer; Sorafenib; Vinorelbine

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BEVACIZUMAB; ESTROGEN RECEPTOR; GLUCOSE; NAVELBINE; PHOSPHATE; PROGESTERONE RECEPTOR; SODIUM; SORAFENIB; TRIACYLGLYCEROL LIPASE;

ABSCESS; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALKALOSIS; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BREAST METASTASIS; CANCER SURVIVAL; CELLULITIS; CLINICAL ARTICLE; COUGHING; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENITAL ABSCESS; GLUCOSE BLOOD LEVEL; HAND FOOT SYNDROME; HEADACHE; HICCUP; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; LUNG EMBOLISM; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PHOSPHATE BLOOD LEVEL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SODIUM BLOOD LEVEL; SOMNOLENCE; SURVIVAL RATE; THROMBOCYTOPENIA; TIME TO TREATMENT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE;

BEVACIZUMAB; KINASE INHIBITOR; METASTATIC BREAST CANCER; SORAFENIB; VINORELBINE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; SURVIVAL RATE; VINBLASTINE;

EID: 84896402014     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.10.013     Document Type: Article

References (30)

1. R. Siegel, C. DeSantis, and K. Virgo et al. Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 62 2012 220 241
2. S.K. Chia, C.H. Speers, and Y. D'Yachkova et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer Cancer 110 2007 973 979 (Pubitemid 47312861)
3. Altekruse S, Kosary C, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. Available at: http://seer.cancer.gov/archive/csr/1975-2007/. Accessed:June 14, 2013.
4. S.M. Wilhelm, C. Carter, and L. Tang et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109 (Pubitemid 39331023)
5. R.A. Hilger, M.E. Scheykebm, and D. Strumberg The Ras-Raf-MEK-ERK pathway in the treatment of cancer Onkologie 25 2002 511 518 (Pubitemid 36173389)
6. F. Chang, L.S. Steelman, and J.G. Shelton et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review) Int J Oncol 22 2003 469 480
7. D.A. Altomare, and J.R. Testa Perturbations of the AKT signaling pathway in human cancer Oncogene 24 2005 7455 7464 (Pubitemid 41637985)
8. S. Wilhelm, C. Carter, and M. Lynch et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat Rev Drug Discov 5 2006 835 844 (Pubitemid 44480537)
9. A. Moreno-Aspitia, R.F. Morton, and D.W. Hillman et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336 J Clin Oncol 27 2009 11 15
10. G. Bianchi, S. Loibl, and C. Zamagmi et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer Anticancer Drugs 20 2009 616 624
11. C.A. Carter, C. Chen, and C. Brink et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma Cancer Chemother Pharmacol 59 2007 183 195 (Pubitemid 44885148)
12. J. Baselga, J.G. Segalla, and H. Roché et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER-2-negative locally advanced or metastatic breast cancer J Clin Oncol 30 2012 1484 1491
13. W.J. Gradishar, V. Kaklamani, and T.P. Sahoo et al. A double-blind, randomized, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer Eur J Cancer 49 2013 312 322
14. C. Hudis, K.W. Tauer, and R.C. Hermann et al. Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV) J Clin Oncol 29 suppl 2011 (abstract 1009)
15. G. Mariani, O. Burdaeva, and L. Roman et al. A double-blind, randomized phase IIb study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with docetaxel and/or letrozole in patients with metastatic breast cancer (MBC): FM-B07-01 trial Eur J Cancer 47 suppl 2 2011 10 (abstract)
16. J. Baselga, F. Costa, and H. Gomez et al. A phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer (the RESILIENCE study): study protocol for a randomized controlled trial Trials 14 2013 228
17. M. Mano Vinorelbine in the management of breast cancer: new perspectives, revived role in the era of targeted therapy Cancer Treat Rev 32 2006 106 118 (Pubitemid 43362232)
18. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
19. N.A. Rizvi, G.J. Riely, and C.G. Azzoli et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer J Clin Oncol 26 2008 639 643 (Pubitemid 351264360)
20. K. Miller, M. Wang, and J. Gralow et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
21. N.J. Robert, V. Dieras, and J. Glaspy et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 2011 1252 1260
22. J. O'Shaughnessy, D. Miles, and R. Gray et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC) J Clin Oncol 28 suppl 2010 (abstract 1005)
23. A. Brufsky, S. Hurvitz, and E. Perez et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor 2-negative metastatic breast cancer J Clin Oncol 29 2011 4286 4293
24. K.D. Miller, L.I. Chap, and F.A. Holmes et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 2005 792 799 (Pubitemid 46224178)
25. K.J. Gotink, and H.M. Verheul Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13 2010 1 14
26. R.K. Jain, D.G. Duda, and C.G. Willett et al. Biomarkers of response and resistance to antiangiogenic therapy Nat Rev Clin Oncol 6 2009 327 338
27. N. Denduluri, S.X. Yang, and A.W. Berman et al. Circulating biomarkers of bevacizumab activity in patients with breast cancer Cancer Biol Ther 7 2008 15 20 (Pubitemid 351590445)
28. N. Murukesh, C. Dive, and G.C. Jayson Biomarkers of angiogenesis and their role in the development of VEGF inhibitors Br J Cancer 102 2010 8 18
29. H.J. Burstein, A.D. Elias, and H.S. Rugo et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 2008 1810 1816
30. A. Liljegren, J. Bergh, and R. Castany Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer Breast 18 2009 259 262